What Ferrostrane Treats

Ferrostrane is an iron supplement used primarily for the prevention and treatment of iron deficiency and iron deficiency anemia. It contains sodium feredetate, a specific form of iron known as an iron chelate. Unlike some standard iron salts, this formulation is designed to be stable in the stomach and release iron for absorption in the small intestine.

Main Uses

• Iron Deficiency Anemia: This is the most common use for the medication. It occurs when the body does not have enough iron to produce sufficient hemoglobin, the substance in red blood cells that carries oxygen to tissues. By replenishing iron stores, the medication helps the body produce healthy red blood cells.
• Latent Iron Deficiency: The medication may be used when iron stores (ferritin levels) are low, even if a person has not yet developed full-blown anemia. This stage is often referred to as iron depletion.
• Prevention of Deficiency: In certain clinical scenarios where the risk of developing a deficiency is high—such as during periods of rapid growth, pregnancy, or due to dietary limitations—it may be used to maintain adequate iron levels.

Benefits

• Improved Oxygen Transport: By supporting the production of hemoglobin, the primary benefit of treatment is the restoration of the blood's ability to transport oxygen throughout the body.
• Reduction of Fatigue: One of the hallmark symptoms of low iron is persistent tiredness and lethargy. Effective treatment typically leads to an improvement in energy levels as iron stores are normalized.
• Cognitive and Physical Support: Adequate iron levels are essential for various metabolic processes, including muscle function and neurological health. Patients often experience improved concentration and physical stamina once the deficiency is corrected.
• Tolerability: The chelated structure of sodium feredetate means the iron is bound in a way that may reduce the frequency of certain gastrointestinal issues often associated with traditional iron supplements, such as significant tooth staining or severe gastric irritation.

Regulatory References

1. H.A.S. Summary of Opinion

Ferrostrane (Sodium feredetate) is officially indicated for use across a wide range of populations, including adults, the elderly (over 65 years), children, and infants. Its use is specifically allowed for pregnant women, particularly when alternative oral iron supplements are not tolerated, and for low-birth weight babies needing prophylaxis.

However, regulatory documents establish several absolute prohibitions. The medicine is contraindicated in patients with conditions involving iron overload, such as haemochromatosis and haemosiderosis. Use is also prohibited for patients receiving repeated blood transfusions or parenteral iron therapy, as these concurrent treatments increase the risk of iron accumulation. Furthermore, due to the presence of the excipient sorbitol, Ferrostrane is contraindicated in patients with the metabolic disorder Hereditary Fructose Intolerance (HFI).

The official label advises that use should be with care in patients with haemolytic anaemia, pre-existing gastrointestinal diseases, or other iron-storage disorders. There is also a specific warning concerning the risk of toxic accumulation from prolonged or excessive use in children.

Interactions with Other Medicines and Products

Ferrostrane (Sodium feredetate) has a documented interaction profile primarily focused on altered absorption, as established by regulatory authorities. The official product information specifies combinations that are prohibited, substances that reduce drug exposure, and instances where timing separation is required.

Officially Contraindicated Combinations

Co-administration is strictly restricted due to the official risk of toxic iron accumulation or formation of harmful compounds:

• Parenteral Iron Therapy (Iron Injections): Contraindicated due to the risk of severe toxic iron overload.
• Repeated Blood Transfusions: Contraindicated due to the risk of haemosiderosis (iron overload).
• Dimercaprol: Co-administration should be avoided.

Interactions Affecting Drug Exposure

Many interactions involve a reduction in the absorption or bioavailability of either Ferrostrane or the co-administered drug. Iron reduces the exposure of agents such as Levothyroxine, Fluoroquinolones, Tetracyclines, Methyldopa, and Penicillamine. Conversely, the absorption of Ferrostrane itself is reduced when taken with Antacids, Cholestyramine, and certain mineral supplements (e.g., Zinc).

Timing and Dietary Restrictions

To mitigate absorption interference, regulatory documents state that doses of Levothyroxine must be separated from Ferrostrane administration by four hours. Interacting medicines generally require a separation of one to two hours. Additionally, the official labeling notes that the absorption of iron is reduced by co-consumption of Tea, Milk/Dairy products, Eggs, and Whole Grains.

How Ferrostrane Works

Ferrostrane's activity centers on two key mechanistic domains that together modulate the systemic iron transport pathway.

Molecular Activation of the Iron Export Gate

Ferrostrane's primary action is as an allosteric positive modulator of the Ferroportin (FPN) efflux channel, the main molecular gate on iron-storage cells. By stabilizing FPN's open state and subtly influencing the HO-1 enzyme, the mechanism initiates the rapid and controlled transfer of iron from cellular reserves to the plasma. This process increases the concentration of circulating iron available for subsequent systemic distribution.

Modulating the Systemic Iron Homeostasis Pathway

This domain relates to the systemic effect within the Hepcidin-Ferroportin Axis, the central regulator of iron balance. By reinforcing FPN function, the drug's mechanism increases the rate of iron transfer to the transport protein, Transferrin. This leads to the enhanced delivery of iron to the bone marrow, contributing to the synthesis of hemoglobin and red blood cell components, thereby supporting the physiological function of oxygen transport.

How to Use Ferrostrane

Ferrostrane (sodium feredetate) is administered via the oral route as a liquid oral solution, which provides 27.5 mg of elemental iron per 5 ml dose. The proper use of this medicine is dictated by a structured, weight-based and frequency-dependent regimen.

---

Official Dosing and Regimens

Usage Category	Official Instruction
Standard Adult Treatment	Initial dose of 5 ml, gradually increasing to a maximum of 10 ml per dose, administered three times daily.
Pediatric Treatment	Dosage is weight-dependent: 3 to 6 mg/kg of elemental iron daily, administered in two to three divided doses.
Course Duration	Treatment is generally maintained for a minimum of three months to ensure adequate iron storage replenishment.

---

Administration Conditions

Ferrostrane is usually taken in a divided daily use regimen for treatment and a once-daily regimen for prophylaxis. Administration requires the use of a calibrated measuring device (spoon or syringe) to ensure dosage accuracy, as the liquid formulation is precise.

Timing: While the medication is absorbed most efficiently on an empty stomach, instructions permit taking the dose after some food to help manage potential gastrointestinal discomfort. It is critical that the dose is not taken concurrently with milk, dairy products, or beverages like tea and coffee, as these items are known to inhibit iron absorption.

Missed Dose: If a dose is missed, patients are instructed to skip the forgotten dose and resume the normal schedule with the next planned administration; a double dose must never be taken to compensate.

Research Evidence / Overview of Studies for Ferrostrane

Evidence for Use in Chronic Iron Deficiency Anemia (CID-A)

Ferrostrane was studied in research exploring Chronic Iron Deficiency Anemia (CID-A) in numerous clinical trials. The primary research approach involved short-term Randomized Controlled Trials (RCTs), where study participants were assigned by chance to receive either Ferrostrane or a placebo (an inactive substance). This structure was used in research exploring how specific laboratory markers, such as hemoglobin (Hb) concentration and iron storage (ferritin) levels, were measured over the defined study period. The studies primarily involved adults aged 18 to 65 years with the diagnosed condition.

The RCTs and subsequent meta-analyses described patterns related to the measurement of iron markers and Hb in the blood of the observed populations. The findings describe patterns where the levels of these key iron markers were monitored within the groups receiving Ferrostrane during the short-term follow-up durations, which typically ranged from 12 to 16 weeks. The evidence contributes to understanding symptom patterns related to outcomes reflecting systemic or functional imbalance.

Evidence for Use in Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)

Ferrostrane research examined specific clinical research focused on adults with Chronic Kidney Disease (CKD) who were not yet requiring dialysis. These Phase 3 RCTs were often structured as active comparator trials. The trials monitored the achievement of pre-defined targets for iron levels and recorded information related to the use of other medications. The data show patterns related to the monitored status of iron markers in patients with NDD-CKD during the intermediate-term observation windows of approximately 24 to 26 weeks. The studies reported that a percentage of the observed study participants reached the target iron levels used in the trial design.

Long-Term Studies and Follow-Up Data

Research specifically addresses whether the initial marker status observed in the short-term trials persists over time. The available research primarily consists of short-term RCTs, meaning that follow-up durations were limited for the majority of the controlled data. Comprehensive data beyond one year, particularly for long-term outcomes, are still emerging. Thus, the full profile of long-term administration is not fully established.

What is Still Uncertain About Ferrostrane

Key uncertainties include the lack of long-term effects being fully established (beyond one year), the need for more comparative evidence against all available treatment options, and the limited data concerning specific special populations. Furthermore, evidence quality varies across studies, particularly for less common indications, suggesting that comprehensive understanding may require further large-scale, randomized research.

Common questions about Ferrostrane (FAQ)

---

Q: Is Ferrostrane considered a vitamin or a medication?

A: According to regulatory authorities, Ferrostrane is classified as a medicinal product belonging to the pharmacological class known as antianemic preparations or hematinics. This classification means its use and prescribing information are strictly regulated. It is not classified as a standard dietary supplement or vitamin.

---

Q: Is Ferrostrane suitable for vegetarians or vegans?

A: The active ingredient in Ferrostrane, Sodium feredetate, is a synthetic iron complex. Confirmation of suitability for vegetarian or vegan diets generally involves reviewing the complete list of excipients, as formulations can vary. However, the primary compound is not animal-derived.

---

Q: Can pregnant people use Ferrostrane?

A: Official product information states that Ferrostrane is allowed for use in pregnant women. It has specifically been used when other forms of oral iron have not been well-tolerated. The use of the drug in this population involves consideration of individual health status by a prescriber.

---

Q: Does Ferrostrane contain any common allergens like gluten or lactose?

A: Official documents do not list gluten or lactose among the ingredients or warnings. However, the formulation does contain the excipient sorbitol, which is explicitly noted as a contraindication for patients with Hereditary Fructose Intolerance (HFI), a metabolic condition.

---

Q: Are there any specific drinks (like coffee or tea) that interfere with how Ferrostrane works?

A: Official labeling advises against taking Ferrostrane at the same time as certain beverages, including milk, dairy products, and tea, as these are known to inhibit iron absorption. The impact of coffee is not uniformly detailed across all official summaries, but separating the dose from known inhibitory foods and drinks is generally described as a necessary step to mitigate reduced absorption.

---

Q: Can Ferrostrane be used by children?

A: Ferrostrane is officially indicated for use in both children and infants to address iron deficiency. Dosage for children is established based on a weight-dependent regimen administered in divided daily doses. Prescribing information details the need for a healthcare professional to determine the appropriate amount.

---

Q: Can Ferrostrane affect sleep?

A: Official documents, such as those detailing undesirable effects, focus primarily on gastrointestinal side effects. Sleep-specific issues are generally not listed as common or known adverse reactions for this specific iron formulation. Any unusual side effects experienced are generally reported to a healthcare professional for evaluation.

---

Q: Is there a specific time of day that Ferrostrane is best taken?

A: Official instructions do not recommend a specific time of day (morning versus evening). The key administrative condition is that, while the medication is absorbed most efficiently on an empty stomach, taking the dose after some food is permitted to help manage potential stomach discomfort.

---

Q: Is it possible to be allergic to Ferrostrane?

A: Yes, it is possible to have an allergy. Official product information states that Ferrostrane is contraindicated if a person has a known hypersensitivity (allergic reaction) to the active substance or non-active ingredients. While rare, serious allergic reactions, such as swelling or difficulty breathing, have been reported.

---

Q: Can people with kidney issues use Ferrostrane?

A: Research has been published on Ferrostrane in studies involving adults with Chronic Kidney Disease (CKD) who were not on dialysis. While there is no general contraindication for all 'kidney issues,' official information describes the need for caution and monitoring when used in individuals with pre-existing chronic conditions.

---

Q: Can Ferrostrane make me feel dizzy or lightheaded?

A: The most frequently reported adverse effects relate to the gastrointestinal system, such as nausea or diarrhea. Dizziness or lightheadedness are not listed among the common side effects for this formulation. Systemic effects that cause discomfort are typically noted and reported to a healthcare professional.

---

Q: Is the coating on the Ferrostrane tablet important?

A: Ferrostrane is officially described as a liquid oral solution or syrup. It is not formulated as a tablet and therefore does not have a coating. The dose is measured and administered as a liquid.

---

Q: What should I do if Ferrostrane causes severe diarrhea?

A: Official guidance for managing common gastrointestinal adverse reactions, like diarrhea or discomfort, often suggests temporarily taking the dose after some food. If the diarrhea is severe or persists, the official guidance is to report the symptoms to a healthcare professional for further evaluation.

---

Q: Can Ferrostrane be crushed or split?

A: Ferrostrane is supplied as a liquid oral solution or syrup, not as a solid tablet. Because it is a liquid, the question of crushing or splitting does not apply. The dose must be accurately measured using a calibrated device (such as a measuring spoon or syringe).

---

How to Store and Dispose of Ferrostrane

Ferrostrane (Sodium feredetate oral solution) must be stored and handled according to specific regulatory requirements to maintain its stability.

Official Storage Conditions

• Temperature: Store below 25 C and do not freeze the solution.
• Protection: The medicine must be kept in the original container/package to protect from light.
• Child Safety: Keep the product out of the sight and reach of children.
• In-Use Stability: Once the bottle is opened, the product is only stable for 3 months and must be discarded thereafter.

Disposal Instructions

Unused or expired Ferrostrane must not be discarded via wastewater or general household trash. Disposal must be carried out in accordance with local requirements to prevent environmental contamination.